Cardiovascular Immunotherapy and the Role of Imaging

Zupančič, Eva; Fayad, Zahi A.; Mulder, Willem J. M.

doi:10.1161/atvbaha.117.309227

Cited by 5 publications

(5 citation statements)

References 85 publications

(89 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One strategy is to target the immune system's ability to regulate arterial inflammation, for instance, neutralizing proinflammatory cytokines such as IL-1β to resolve inflammatory atherosclerosis. Maintaining tissue homeostasis and repairing lesions are also possibilities, which can be carried out through the action of cytokines such as IL-4 and IL-13 [13].…”

Section: Meta-analysismentioning

confidence: 99%

Association of functional IL16 polymorphisms with cancer and cardiovascular disease: a meta-analysis

et al. 2020

View full text Add to dashboard Cite

Introduction: Interleukin-16 (IL-16) is a chemotactic cytokine that is found to increase in Cancer and cardiovascular diseases (CVD). Single nucleotide polymorphisms (SNPs) in IL16 were associated with diseases. Thus, we conducted a systematic review and meta-analysis to evaluate possible associations between IL16 rs4778889, rs11556218, rs4072111, and rs1131445 SNPs and the risk for cancer or CVD. Materials and Methods: This study was performed according to the PRISMA statement. Medline, Web of Science, and Scopus databases were systematically reviewed, and a meta-analysis was conducted. Results: The analysis comprised 6386 individuals with cancer and 2415 with CVD. The SNP rs11556218 was significantly associated with an increased risk for cancer in Chinese in different genetic inheritance models. Also, to the best of our knowledge, this is the first meta-analysis to show an association of rs4778889 with an increased risk of gastric cancer and rs11556218 with an increased risk of CVD in Chinese. Conclusions: Our meta-analysis suggested that the SNPs rs11556218 and rs4778889 of IL16 were associated with an increased risk for cancer in Chinese and rs11556218 with increased risk for CVD in Chinese, highlighting the need for further studies on the impact of these polymorphisms on cancer treatment and surveillance.

show abstract

Section: Meta-analysismentioning

confidence: 99%

Association of functional IL16 polymorphisms with cancer and cardiovascular disease: a meta-analysis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study) has shown that subcutaneous injections of canakinumab (ACZ885), a human monoclonal antibody that selectively neutralizes IL-1β, significantly reduced levels of systemic inflammatory biomarkers in patients after acute myocardial infarction, reducing risk cardiovascular disease in patients with previous heart attack and inflammatory atherosclerosis. 20 Another study using CANTOS reinforces this idea and provides strong evidence that the modulation of the IL-6-induced signaling pathway induced by IL-1α is associated with reduced rates of cardiovascular changes and mortality. 13…”

Section: Introductionmentioning

confidence: 78%

“…If alterations in macrophages' function are linked to these clinical conditions, immunotherapy with macrophage reprogramming in situ could be a reliable form of therapeutic strategy that could be applied to ensure normal cardiac rhythm in patients with signs of arrhythmia. 20,21 However, what we know so far is that resident macrophages act as "masters", orchestrating the heart rate.…”

Section: Introductionmentioning

confidence: 99%

Resident Macrophages Orchestrating Heart Rate

Souza

Barreto

Santana

et al. 2019

Arquivos Brasileiros De Cardiologia

View full text Add to dashboard Cite

“…Change in TBR MDS, the primary outcome, relates to how responsive the atherosclerotic plaques may be to interventions, such as immunomodulators that were used in the TARGET trial. 59 As well, change in TBR MDS can denote future risk of CVD. Baseline TBR MDS reflects arterial inflammation at a time when RA was active and not well controlled by methotrexate alone and may not correlate with treatment responsiveness or future cardiovascular risk.…”

Section: Discussionmentioning

confidence: 99%

Biomarkers of Cardiovascular Risk in Patients With Rheumatoid Arthritis: Results From the TARGET Trial

Solomon,

Demler,

Rist

et al. 2024

JAHA

View full text Add to dashboard Cite

Background Cardiovascular disease remains an important comorbidity in patients with rheumatoid arthritis (RA), but traditional models do not accurately predict cardiovascular risk in patients with RA. The addition of biomarkers could improve prediction. Methods and Results The TARGET (Treatments Against RA and Effect on FDG PET/CT) trial assessed whether different treatment strategies in RA differentially impact cardiovascular risk as measured by the change in arterial inflammation on arterial target to background ratio on fluorodeoxyglucose positron emission tomography/computed tomography scans conducted 24 weeks apart. A group of 24 candidate biomarkers supported by prior literature was assessed at baseline and 24 weeks later. Longitudinal analyses examined the association between baseline biomarker values, measured in plasma EDTA, and the change in arterial inflammation target to background ratio. Model fit was assessed for the candidate biomarkers only, clinical variables only, and models combining both. One hundred nine patients with median (interquartile range) age 58 years (53–65 years), RA duration 1.4 years (0.5–6.6 years), and 82% women had biomarkers assessed at baseline and follow‐up. Because the main trial analyses demonstrated significant target to background ratio decreases with both treatment strategies but no difference across treatment groups, we analyzed all patients together. Baseline values of serum amyloid A, C‐reactive protein, soluble tumor necrosis factor receptor 1, adiponectin, YKL‐40, and osteoprotegerin were associated with significant change in target to background ratio. When selected candidate biomarkers were added to the clinical variables, the adjusted R 2 improved from 0.20 to 0.33 (likelihood ratio P =0.0005). Conclusions A candidate biomarker approach identified several promising biomarkers that associate with baseline and treatment‐associated changes in arterial inflammation in patients with RA. These will now be tested in an external validation cohort.

show abstract

Cardiovascular Immunotherapy and the Role of Imaging

Cited by 5 publications

References 85 publications

Association of functional IL16 polymorphisms with cancer and cardiovascular disease: a meta-analysis

Association of functional IL16 polymorphisms with cancer and cardiovascular disease: a meta-analysis

Resident Macrophages Orchestrating Heart Rate

Biomarkers of Cardiovascular Risk in Patients With Rheumatoid Arthritis: Results From the TARGET Trial

Contact Info

Product

Resources

About